NCT02022696View on ClinicalTrials.gov

Treatment of SCID Due to ADA Deficiency With Autologous Transplantation of Cord Blood or Hematopoietic CD 34+ Cells After Addition of a Normal Human ADA cDNA by the EFS-ADA Lentiviral Vector

PHASE1CompletedINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

December 16, 2013

Primary Completion Date

December 16, 2013

Study Completion Date

September 21, 2017

Conditions
Adenosine Deaminase DeficiencyADA-SCID
Interventions
GENETIC

Lentiviral Gene Transfer

Trial Locations (1)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

All Listed Sponsors
collaborator

UCLA@@@Duke University Medical Center

UNKNOWN

collaborator

Duke Univ. Medical Center

UNKNOWN

collaborator

National Cancer Institute (NCI)

NIH

collaborator

National Institutes of Health Clinical Center (CC)

NIH

lead

National Human Genome Research Institute (NHGRI)

NIH

NCT02022696 - Treatment of SCID Due to ADA Deficiency With Autologous Transplantation of Cord Blood or Hematopoietic CD 34+ Cells After Addition of a Normal Human ADA cDNA by the EFS-ADA Lentiviral Vector | Biotech Hunter | Biotech Hunter